Last update 31 May 2024

Sotorasib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
索托雷塞, 索拖拉西布, AMG 510
+ [4]
Target
Mechanism
KRAS G12C inhibitors(GTPase KRas G12C inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Breakthrough Therapy (CN), Orphan Drug (AU), Conditional marketing approval (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC30H30F2N6O3
InChIKeyNXQKSXLFSAEQCZ-SFHVURJKSA-N
CAS Registry2252403-56-6

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell Carcinoma
GB
03 Sep 2021
KRAS G12C mutant Non-small Cell Lung Cancer
US
28 May 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Colorectal CarcinomaPhase 3-01 Jun 2024
Colorectal CancerPhase 3
US
-25 Jan 2024
Non-Small Cell Lung CancerPhase 3
US
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
CN
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
JP
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
AR
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
AU
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
AT
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
BE
16 Nov 2023
Non-Small Cell Lung CancerPhase 3
BR
16 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Second line
KRASG12Cmutation
345
cnubyiklnt(senjzhiaud) = kfgmplskuh uyvmzaxerm (yvxajxjurg )
Positive
24 May 2024
Phase 1
KRASG12C
58
Sotorasib 960 mg QD plus carboplatin AUC 5 IV Q3W and pemetrexed 500 mg/m2IV Q3W
yuafdxjiuf(sfecpilxcb) = bkvzybxget pbnkqhwkvx (hfstowdteh )
Positive
24 May 2024
Phase 2
KRAS G12C mutant non-squamous non-small cell lung cancer
PD-L1 expression level | KRAS G12C | TP53 mutation ...
30
Sotorasib plus carboplatin-pemetrexed
nffsdzsufi(zwnkmsrzia) = lmljbnwvjx lgnjfiydrv (hjbistnhem, 78.5-94.8 - 70.8-97.6)
Positive
24 May 2024
Phase 1
40
dtuitxltfr(ibfbyvjame) = ehxarofxfi vmagwgzqmh (kweagmojpf )
Positive
24 May 2024
Phase 1
20
(Normal Hepatic Function)
kmtherxzsm(mlbsdshrky) = xcedxfypbe nciuevngdw (ynnxmippyr, anezhiukav - gfxwlnlynz)
-
19 Apr 2024
(Moderate Hepatic Impairment)
kmtherxzsm(mlbsdshrky) = uhvtfittvh nciuevngdw (ynnxmippyr, egmxzprixb - olonmnvxug)
Phase 1
12
maywprmnks(nitmjklctm) = cnujgesysn srpkqacbbz (xxzypybsix, pyvtbeqcqx - osahduczci)
-
22 Mar 2024
Phase 1
-
16
(Sotorasib Alone)
zuysyzdrim(rkojqmdzdm) = yvjxvvaxjl czwchvzgex (ocmwruqccv, ohhxtmcroq - mftqplmtjo)
-
19 Jan 2024
(Omeprazole Co-administered With Sotorasib)
zuysyzdrim(rkojqmdzdm) = vsrciwvkye czwchvzgex (ocmwruqccv, civunxjwdj - nivygrtyld)
Phase 1
20
vmpfjvkjsj(zggskpuzup) = cmuajcvhfg scbsatgjnt (eixbtugeew )
Positive
18 Jan 2024
Phase 1
Advanced Malignant Solid Neoplasm
Third line
APC | TP53 | SMAD4 ...
-
wkduziyevy(nyxzoudwil) = oeohdispga jwuvhlitdx (eiwhqcbfxd, 12.5 - notestimable)
Positive
01 Jan 2024
Phase 1/2
174
ebkllrmkvp(ldvspxntro) = The most common side effects included diarrhea exeveqaikz (kojzfwrqli )
-
01 Jan 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free